Navitas Life Sciences provided end-to-end support to a US Based mid-size biotech company in the development of their first in class therapy for critically ill covid patients. The Phase I study had been conducted in the US, and the company needed a partner to conduct the Phase II study in multiple countries - USA, India and other potential countries.

Navitas Life Sciences’ experienced Medical writers, Medical Leads and Biostatistics teams collaborated to deliver a well designed innovative and adaptive, two stage study protocol within a short span.

Download this Case Study to Learn how we:

• Developed a robust study protocol
• Completed the study in a short span
• Received Appreciation from the USFDA

Please complete the form to download our Case Study.

© 2024 Navitas Life Sciences | Privacy Policy